MedTrace Logo

Peri-operative Sintilimab in Combination With SOX in Locally Advanced Gastric Cancer

NCT04982939 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 210

Last updated 2021-08-31

No results posted yet for this study

Summary

To evaluate efficacy and safety of peri-operative sintilimab in combination with SOX in resectable locally advanced gastric or gastroesophageal junction adenocarcinoma

Conditions

Interventions

DRUG

Sintilimab

Sintilimab, 200mg IV d1 Q3W

DRUG

S-1

S-1, 40-60mg BID d1-14 Q3W

DRUG

Oxaliplatin

Oxaliplatin，130mg/m2 d1 Q3W

Sponsors & Collaborators

  • Tianjin Medical University Cancer Institute and Hospital

    lead OTHER

Principal Investigators

  • Han Liang, PhD. · Tianjin Medical University Cancer Institute and Hospital

  • Xuewei Ding, PhD. · Tianjin Medical University Cancer Institute and Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-21
Primary Completion
2023-06-21
Completion
2024-06-21

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04982939 on ClinicalTrials.gov